Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-Dec-2022
Document Type: USP Monographs
DocId: GUID-064463C3-C7CE-40B3-BD01-24F0F457E83A_2_en-US
DOI: https://doi.org/10.31003/USPNF_M54593_02_01
DOI Ref: n6zox

Mometasone Furoate Topical Solution

DEFINITION

Mometasone Furoate Topical Solution is Mometasone Furoate in a suitable aqueous vehicle. It contains NLT 90.0% and NMT 110.0% of the labeled amount of mometasone furoate ($C_{27}H_{30}Cl_2O_6$).

IDENTIFICATION

Change to read:

• **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*▲▲ (ERR 1-Dec-2022) , as obtained in the *Assay*.

• **B. Thin-Layer Chromatographic Identification Test ⟨201⟩**

Standard solution: 1 mg/mL of USP Mometasone Furoate RS in a mixture of chloroform and methanol (4:1)

Sample solution: Transfer the equivalent of 2 mg of mometasone furoate from Topical Solution to a 50-mL centrifuge tube. Add 10 mL of water. Extract the aqueous solution with 20 mL of chloroform. Remove the chloroform layer, dry over anhydrous sodium sulfate, and filter through a cotton pledget. Repeat the chloroform extraction, and combine the dried extracts. Evaporate the chloroform solution to dryness on a steam bath under a stream of nitrogen. Allow the sample specimen to cool to room temperature. Dissolve the residue in a mixture of chloroform and methanol (4:1) to obtain 1 mg/mL of *Sample solution*.

Application volume: 20 µL

Developing solvent system: Chloroform and ethyl acetate (3:1)

Acceptance criteria: The R_F value of the principal spot of the *Sample solution* corresponds to the that of the *Standard solution*.

ASSAY

• **Procedure**

[Note—Protect from light.]

Diluent: Acetonitrile, water, and glacial acetic acid (50:50:1)

Solution A: Water

Solution B: Acetonitrile

Mobile phase: See *Table 1*.

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	70	30
2	70	30
45	45	55
46	70	30
50	70	30

Standard solution: 0.1 mg/mL of USP Mometasone Furoate RS in *Solution B*

Sample solution: Transfer a portion of Topical Solution, equivalent to about 2.5 mg of mometasone furoate, to a 25-mL flask. Dilute with *Diluent* to volume, and mix. Pass a portion of the solution through a polypropylene filter of 0.2-µm pore size, discarding the first 1–2 mL of filtrate.

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm × 25-cm; 5-µm packing L60

Flow rate: 2 mL/min

Injection size: 50 µL

System suitability

Sample: *Standard solution*

Suitability requirements:

Tailing factor: NMT 1.5 for the mometasone furoate peak

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of mometasone furoate ($C_{27}H_{30}Cl_2O_6$) in the portion of Topical Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of USP Mometasone Furoate RS in the *Standard solution* (mg/mL)

C_U = nominal concentration of mometasone furoate in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

IMPURITIES

• **Organic Impurities**

[Note—Protect from light.]

Diluent, Solution A, Solution B, Mobile phase, Standard solution, and **Sample solution:** Prepare as directed in the *Assay*.

System suitability solution: 0.1 µg/mL of USP Mometasone Furoate RS from *Standard solution* in *Diluent*

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm × 25-cm; 5-µm packing L60

Column temperature: 25 ± 5°

Flow rate: 2 mL/min

Injection size: 50 µL

System suitability

Sample: *System suitability solution*

Suitability requirements

Relative standard deviation: NMT 10%

Analysis

Samples: *Diluent*, *System suitability solution*, and *Sample solution*

[Note—Exclude any peak areas less than that of the *System suitability solution*. Also, exclude any peaks with the same retention times as those observed in the *Diluent*. Any peaks having a relative retention time of 1.04 or 1.13 are controlled in the *Mometasone Furoate* monograph, and therefore are not included in the total specified and unspecified impurities limit.]

Calculate the percentage of each impurity in the portion of Topical Solution taken:

$$\text{Result} = (r_U/r_T) \times 100$$

r_U = peak response of each impurity from the *Sample solution*

r_T = sum of all the peak responses from the *Sample solution*

Acceptance criteria: See *Table 2*.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
9α-Chloro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)	0.56	0.3
9α,21-Dichloro-11β,17-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione	0.73	0.1
21-Chloro-17-hydroxy-16α-methylpregna-1,4-diene-3,11,20-trione 17-(2-furoate)	0.88	0.1
21-Chloro-9β,11β-epoxy-17-hydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)	0.94	1.0
Mometasone furoate	1.0	—
Unspecified individual impurity	—	0.5
Total specified and unspecified impurities	—	2.0

SPECIFIC TESTS

• **Microbial Enumeration Tests ⟨61⟩** and **Tests for Specified Microorganisms ⟨62⟩:** It meets the requirements of the tests for absence of *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Salmonella* species.

• **pH ⟨791⟩:** 4.0–5.0

ADDITIONAL REQUIREMENTS

• **Packaging and Storage:** Preserve in well-closed containers, and store at controlled room temperature.

• **USP Reference Standards ⟨11⟩**

USP Mometasone Furoate RS

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Expert Committee
MOMETASONE FUROATE TOPICAL SOLUTION	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. 50(1)

Current DocID: GUID-064463C3-C7CE-40B3-BD01-24F0F457E83A_2_en-US

DOI: https://doi.org/10.31003/USPNF_M54593_02_01

DOI ref: n6zox